RGEN — Repligen Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Repligen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	366	671	802	632	634
Cost of Revenue
Gross Profit	210	391	456	309	319
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	296	503	577	597	669
Operating Profit	69.8	167	225	35	-34.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	59.2	154	219	56.7	-27
Provision for Income Taxes
Net Income After Taxes	59.9	128	186	35.6	-25.5
Net Income Before Extraordinary Items
Net Income	59.9	128	186	35.6	-25.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	59.9	128	186	35.6	-25.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.58	2.46	3.53	1.13	0.14